Analytical Data
-
Gene name
VEGF183
-
简介
VEGF183 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF183 Protein, Human (sf9) is the recombinant human-derived VEGF183 protein, expressed by Sf9 insect cells , with tag free. The total length of VEGF183 Protein, Human (sf9) is 183 a.a., with molecular weight of ~21 KDa.
- Application
-
Alternative Names
VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGF
-
Species
Human
-
Source
Baculovirus
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15692-3
-
Expression Region
A27-R209
-
Protein Length
Partial
-
Molecular Weight
20-30 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular endothelial growth factor (VEGF) is a key signaling protein that plays a crucial role in angiogenesis, the process by which new blood vessels form from pre-existing ones. Among the various isoforms of VEGF, VEGF183 has garnered significant interest due to its unique structural and functional properties. Unlike its other isoforms, VEGF183 has a distinct amino acid sequence that influences its receptor-binding affinity and biological activities. Research has indicated that VEGF183 is closely associated with pathological conditions such as cancer, where its overexpression can lead to enhanced tumor growth and metastasis by promoting excessive neovascularization. Furthermore, studies suggest that targeting VEGF183 may offer potential therapeutic avenues for diseases characterized by abnormal vascular growth, including diabetic retinopathy and age-related macular degeneration. The production of recombinant VEGF183 protein enables researchers to better understand its biological functions and therapeutic potentials, paving the way for the development of novel anti-angiogenic strategies. As the understanding of VEGF183 continues to evolve, its implications in medicine and molecular biology are expected to expand, providing new insights into the regulation of blood vessel formation and its links to various diseases.
